GlyTherix Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$6.55M
- Investors
-
6
GlyTherix General Information
Description
Developer of a targeted radiotherapy platform designed to treat solid tumors by delivering antibody radiopharmaceuticals. The company offers a proprietary antibody, which targets Glypican-1 found only in tumor tissue, enabling patients with prostate, bladder, pancreatic, glioblastoma, oesophageal, and ovarian cancers access to new treatment options where few exist.
Contact Information
Website
www.glytherix.comCorporate Office
- Level 1, 3 Innovation Road
- Macquarie Park, New South Wales 2113
- Australia
Corporate Office
- Level 1, 3 Innovation Road
- Macquarie Park, New South Wales 2113
- Australia
GlyTherix Timeline
GlyTherix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A1) | 16-Feb-2024 | $6.55M | Completed | Clinical Trials - Phase 1 | ||
| 5. Accelerator/Incubator | 13-Oct-2023 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series A) | 22-Jul-2023 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 01-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 16-Jul-2020 | $2.07M | Completed | Startup | ||
| 1. Accelerator/Incubator | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
GlyTherix Patents
GlyTherix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2026908908-A0 | Stable anti-gpc-1 antibodies and uses thereof | Pending | 27-Oct-2026 | ||
| AU-2025904740-A0 | Stable anti-gpc-1 antibodies and uses thereof | Pending | 10-Oct-2025 | ||
| AU-2024903281-A0 | Stable anti-gpc-1 antibodies and uses thereof | Inactive | 11-Oct-2024 | ||
| AU-2023903279-A0 | Stable anti-gpc-1 antibodies and uses thereof | Inactive | 13-Oct-2023 | ||
| AU-2022903168-A0 | Stable anti-gpc-1 antibodies and uses thereof | Inactive | 26-Oct-2022 |
GlyTherix Signals
GlyTherix Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Endless Frontier Labs | Accelerator/Incubator | |||
| Cyclowest | Corporation | Minority | ||
| NSW Government (Energy) | Government | |||
| Therapeutic Innovations Australia | Corporation | |||
| Cooperative Research Centres Projects | Government |
GlyTherix FAQs
-
When was GlyTherix founded?
GlyTherix was founded in 2017.
-
Where is GlyTherix headquartered?
GlyTherix is headquartered in Macquarie Park, Australia.
-
What is the size of GlyTherix?
GlyTherix has 8 total employees.
-
What industry is GlyTherix in?
GlyTherix’s primary industry is Biotechnology.
-
Is GlyTherix a private or public company?
GlyTherix is a Private company.
-
What is GlyTherix’s current revenue?
The current revenue for GlyTherix is .
-
How much funding has GlyTherix raised over time?
GlyTherix has raised $6.55M.
-
Who are GlyTherix’s investors?
Endless Frontier Labs, Cyclowest, NSW Government (Energy), Therapeutic Innovations Australia, and Cooperative Research Centres Projects are 5 of 6 investors who have invested in GlyTherix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process